Manual práctico de Trombosis y Hemostasia de la SETH

— 2 6 7 — 9. M e d i c i n a i n t e n s i v a 2. Hall DP, Lone NI, Watson DM, Stanworth SJ, Walsh TS; for the Intensive Care Study of Coagulopathy (ISOC) Investigators. Factors associated with prophylactic plasma transfusion before vascular catheterization in non-bleeding critically ill adults with prolonged prothrombin time: a case-control study. Br J Anaesth 2012;109:919-27. 3. Collins PW, Macchiavello LI, Lewis SJ, Macartney NJ, Saayman AG, Luddington R, et al. Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. Br J Haematol 2006;135:220-7. 4. Inaba K, Branco BC, Rhee P, Blackbourne LH, Holcomb JB,Teixeira PG, et al. Impact of plasma transfusion in trauma patients who do not require massive transfusion. J Am Coll Surg 2010;210:957-65. 5. McQuilten ZK, Crighton G, Brunskill S, et al. Optimal Dose, Timing and Ratio of Blood Products in Massive Transfusion: Re- sults from a Systematic Review.Transfus Med Rev 2018;32:6-15. 6. Godier A, Greinacher A, Faraoni D, Levy JH, Samama CM. Use of factor concentrates for the management of perioperative ble- eding: guidance from the SSC of the ISTH. J Thromb Haemost 2018;16:170-4. 7. Rossaint R, Bouillon B, CernyV, Coats TJ, Duranteau J, Fernández- Mondéjar E, et al.The European guideline on management of ma- jor bleeding and coagulopathy following trauma: fourth edition. Crit Care 2016;20:100. 8. Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, et al.; CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010;376:23-32. 9. Hunt BJ.The current place of tranexamic acid in the management of bleeding. Anaesthesia 2015;70(Suppl 1):50-3. 10. Hunt BJ. Intensive and critical care. In: Key NS, Makris M, Lillicrap D, editors. Practical Haemostasis andThrombosis. D. Chichester,West Sussex; Hoboken, NJ: JohnWiley & Sons Inc., 2017. p. 414-32. 11. Slichter SJ. Evidence-based platelet transfusion guidelines. Hema- tology Am Soc Hematol Educ Program 2007:2007:172-8. 12. Levi M, Scully M. How I treat disseminated intravascular coagula- tion. Blood 2018;22;131:845-54. 13. Stasi R, Evangelista ML, Stipa E, Buccisano F,Venditti A, Amadori S, et al. Idiopathic thrombocytopenic purpura: current concepts in pa- thophysiology and management.Thromb Haemost 2008;99:4-13. 14. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, López-Rodríguez A, et al. Recombinant human protein CWorld- wide Evaluation in Severe Sepsis (PROWESS) study group. Effi- cacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709. 15. RanieriVM,Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al.; PROWESS-SHOCK Study Group. Drotrecogin alfa (activa- ted) in adults with septic shock. N Engl J Med 2012;366:2055-64. 16. Afshari A,Wetterslev J, Brok J, Møller AM.Antithrombin III for criti- cally ill patients.Cochrane Database Syst Rev 2008;(3):CD005370. 17. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodríguez AL, et al.; OPTIMISTTrial Study Group. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003;290:238-47. 18. WarkentinTE. Hos I diagnose and manage HIT. Hematol Am Soc Hematol Educ Program 2011;2011:143-9. 19. Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, et al. Treatment and prevention of heparin-induced thrombo- cytopenia: antithrombotic therapy and prevention of thrombosis, 9 th ed:American College of Chest Physicians Evidence based Prac- tical Guidelines. Chest 2012;141:e45S-530S. 20. Sekhri V, Mehta N, Rawat N, Lehrman SG, Aronow WS. Mana- gement of massive and nonmassive pulmonary embolism. Arch Med Sci 2012;8:957-69. 21. Kearon C,Akl EA, Ornelas J, Blaivas A, Jiménez D, Bounameaux H, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016;149:315-52. 22. GeertsW, Cook D, Selby R, Etchells E.Venous thromboembolism and its prevention in critical care. J Crit Care 2002;17:93-104. 23. Limpus A, ChaboyerW, McDonald E,Thalib L. Mechanical throm- boprophylaxis in critically ill patients: a systematic review and metaanálisis Am J Crit Care 2006;15:402-10. 24. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clini- cal Practice Guidelines (8 th edition). Chest 2008;133(Suppl 6): 381S-453S. 25. Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin TE, et al. PROTECT Investigators. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 2011;364:1305-14.